Actively Recruiting
Metastases Directed Therapy for Oligometastatic Breast Cancer
Led by National Cancer Institute, Egypt · Updated on 2023-11-22
150
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
CONDITIONS
Official Title
Metastases Directed Therapy for Oligometastatic Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 to 70 years
- Pathological evidence of breast cancer, any grade, any T stage
- Radiological evidence of metastatic activity with a maximum of 5 extracranial lesions
- Performance status of 2 or less
- No pre-existing conditions that would prevent radiotherapy
You will not qualify if you...
- Pregnant or lactating women
- Prior radiotherapy to affected sites within the past year
- Active connective tissue diseases, such as Rheumatoid Arthritis
- Progression to widespread metastatic disease
- Presence of brain metastasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Institute
Cairo, Egypt, 11796
Actively Recruiting
Research Team
R
Rimoun R Boutrus, M.D.
CONTACT
J
Joseph S Nayrouz, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here